Dr. Michael S Gordon, MD
Claim this profileHonor Health Research Institute
Studies Tumors
Studies Solid Tumors
17 reported clinical trials
25 drugs studied
About Michael S Gordon, MD
Education:
- Holds an MD (Doctor of Medicine).
- Earned a PhD in an unspecified field.
Experience:
- Pioneered the creation of Harvey, the first cardiopulmonary patient simulator, at the University of Miami's Leonard M. Miller School of Medicine.
- Developed UMedic, a cutting-edge program for medical education.
- Founded the Michael S. Gordon Center for Research in Medical Education.
- Specializes in Hematology, Medical Oncology, and Internal Medicine at HonorHealth Research Institute.
- Recognized with the AXA Advisors Lifetime Achievement Award for contributions to healthcare.
- Provided significant support and funding for medical education and innovation.
Area of expertise
1Tumors
Stage IV
Stage III
MMR positive
2Solid Tumors
Stage IV
EGFR positive
ROS positive
Affiliated Hospitals
Clinical Trials Michael S Gordon, MD is currently running
Dabrafenib + Trametinib Access
for Cancer
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
Recruiting3 awards Phase 42 criteria
DCSZ11 + Pembrolizumab
for Advanced Cancer
This trial is testing DCSZ11, a drug that helps the immune system attack cancer cells by targeting a specific protein. It is aimed at patients with advanced or metastatic solid tumors. The study will determine the best dose and assess its effectiveness both alone and in combination with another drug, pembrolizumab, which has shown efficacy in various cancers.
Recruiting1 award Phase 1
More about Michael S Gordon, MD
Clinical Trial Related1 year of experience running clinical trials · Led 17 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Michael S Gordon, MD has experience with
- Nivolumab
- Botensilimab
- Pembrolizumab
- Docetaxel
- Dostarlimab
- OR2805
Breakdown of trials Michael S Gordon, MD has run
Tumors
Solid Tumors
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael S Gordon, MD specialize in?
Michael S Gordon, MD focuses on Tumors and Solid Tumors. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are Stage III.
Is Michael S Gordon, MD currently recruiting for clinical trials?
Yes, Michael S Gordon, MD is currently recruiting for 7 clinical trials in Scottsdale Arizona. If you're interested in participating, you should apply.
Are there any treatments that Michael S Gordon, MD has studied deeply?
Yes, Michael S Gordon, MD has studied treatments such as Nivolumab, Botensilimab, Pembrolizumab.
What is the best way to schedule an appointment with Michael S Gordon, MD?
Apply for one of the trials that Michael S Gordon, MD is conducting.
What is the office address of Michael S Gordon, MD?
The office of Michael S Gordon, MD is located at: Honor Health Research Institute, Scottsdale, Arizona 85258 United States. This is the address for their practice at the Honor Health Research Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.